Controversies in the Management of Advanced Ovarian Cancer
|
|
- Ashlee Mills
- 5 years ago
- Views:
Transcription
1 안녕하세요 Controversies in the Management of Advanced Ovarian Cancer Mansoor R. Mirza Nordic Society of Gynaecological Oncology (NSGO) & Rigshospitalet Copenhagen University Hospital, Denmark
2 Primary Debulking Surgery vs. Neoadjuvant Chemotherapy Dose-Dense Weekly vs. 3-Weekly Paclitaxel Intraperitoneal Chemotherapy Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Maintenance PARP Inhibitors or Bevacizumab in Platinum-Sensitive Relapse
3 Vergote I et al. New Engl J Med 2010
4 Vergote I et al. New Engl J Med 2010
5 The MRC CHORUS trial Clinical FIGO stage III/IV ovarian cancer + CA125:CEA ratio > 25 Randomize Imaging +/- clinical evidence of pelvic mass with extra-pelvic metastases Compatible with FIGO stage III/IV Serum CA 125:CEA ratio > 25 Investigation to exclude GI cancer mandated if 25 & serum CEA > ULN Primary surgery followed by chemotherapy Neoadjuvant chemotherapy followed by surgery then chemotherapy Planned to receive carboplatin-based chemotherapy Fit to undergo protocol treatment Written informed consent Kehoe S et al. Lancet 2015
6 Results from the MRC CHORUS trial Progression-Free Survival Proportion alive and progression free N PS NACT Progression Free Survival intention-to-treat population Time from randomisation (months) PS (N=276) NACT (N=274) Events Median (months) (95% CI) HR* (95% CI) 10.3 (9.4, 11.3) 0.90 (0.75, 1.07) 11.7 (10.4, 12.7) PS NACT Kehoe S et al. Lancet 2015 * HR adjusted for baseline stratification factors
7 Results from the MRC CHORUS trial Overall survival Proportion alive Overall survival intention-to-treat population PS (N=276) NACT (N=274) Events Median (months) (95% CI) 22.8 (19.1, 26.0) 24.5 (21.3, 29.1) HR* (95% CI) 0.87 (0.71, 1.05) 1-year OS rate 70% 76% 3-year OS rate 32% 34% 0.00 N PS NACT Time from randomisation (months) PS NACT Kehoe S et al. Lancet 2015 * HR adjusted for baseline stratification factors
8 If a man is offered a fact which goes against his instincts, he will scrutinize it closely, and unless the evidence is overwhelming, he will refuse to believe it. If, on the other hand, he is offered something which affords a reason for acting in accordance to his instincts, he will accept it even on the slightest evidence. The origin of myths is explained in this way. Bertrand Russell author, mathematician, & philosopher ( ), Nobel Prize Laureate
9 Trial in progress GCOG 602 Multicenter (34 specialized institutions), randomized phase III study Clinically diagnosed Stage III/IV ovarian, tubal, and peritoneal carcinoma Balancing factors Institution Stage III/IV PS 0-1/2-3 Age <60/ 60 R a n d o m i z a t i o n Standard arm (STD arm) PDS 4x TC PDS: primary debulking surgery Experimental arm (NAC arm) NAC (4x TC) IDS* IDS TC regimen Paclitaxel 175 mg/m 2 3h iv, day 1 Carboplatin AUC 6.0 iv, day 1, every 21 days 4x TC 4x TC * Optional for Pts with suboptimal PDS Mandatory for Pts with any Ut/Adn/OM not removed 4x TC IDS: interval debulking surgery Takashi Onda et al. Trial in Progress
10 Trial in Progress: TRUST Primary Endpoint: OS ITT population Secondary Endpoints PFS, resection rates, QOL, Fragility Index Strata: FIGO stage, Region, ECOG PS Site qualification process to ensure surgical quality S C P C P C P C P C P C P Site Qualification R Bevacizumab 15mg/sq x 15 C P C P C P S C P C P C P Bevacizumab 15mg/sq x 15 Accrual Status: 355/700 (May2017) S surgery C Carboplatin AUC5 P Paclitaxel 175 mg/sq Mahner S, Elser G, Fotopoulou C, et al. for TRUST
11 Primary Debulking Surgery vs. Neoadjuvant Chemotherapy Dose-Dense Weekly vs. 3-Weekly Paclitaxel Intraperitoneal Chemotherapy Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Maintenance PARP Inhibitors or Bevacizumab in Platinum-Sensitive Relapse
12 JGOG 3016: Dose-Dense weekly paclitaxel Epithelial Ovarian or Peritoneal Stage II - IV No prior therapy Stratified: residual disease, stage, and histology Primary endpoint: PFS Secondary endpoint: OS I Paclitaxel 180 mg/m 2 Carboplatin AUC = 6 x6-9 II Carboplatin AUC = 6 x6-9 Paclitaxel 80 mg/m 2 /w x3 Dose-dense paclitaxel associated with greater hematologic toxicity, and fewer patients completed all protocol therapy Improved PFS with dose-dense weekly paclitaxel Accrual: 637 pts (intent-to-treat) Katsumata N. et al. Lancet, 2009
13 JGOG 3016: Updated Progression-Free Survival JGOG 3016, NOVEL, Japanese Gynecologic Oncology Group median follow-up period: 6.4 years dd-tc c-tc Treatment n Event, n (%) Median PFS P value HR 95%CI dd-tc (63) 28.2 mos c-tc (72) 17.5 mos.
14 JGOG 3016: Updated Overall Survival JGOG 3016, NOVEL, Japanese Gynecologic Oncology Group median follow-up period: 6.4 years Patients surviving (%) dd-tc c-tc Treatment n Deaths, n (%) Median OS 5-yr survival P value HR 95%CI dd-tc (45) not reached 58.7% c-tc (53) 62.2 mos. 51.1%
15 MITO 7: Weekly Carboplatin + Weekly paclitaxel [TITLE] Pignata S et al. ASCO 2013
16 MITO 7: Weekly Carboplatin + Weekly paclitaxel [TITLE] Pignata S et al. ASCO 2013
17 GOG262: Dose-Dense weekly paclitaxel Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer Suboptimal residual disease (optional NACT-ICS) Primary Endpoint: PFS Early perfusion-based CT imaging (ACRIN 6695) I Carboplatin AUC=6 Paclitaxel 80 mg/m 2 (d1,8,15) +/- Bevacizumab (C2-6) $ Bevacizumab q21d $ R II Carboplatin AUC=6 Paclitaxel 175 mg/m 2 (d1) +/- Bevacizumab (C2-6) $ Bevacizumab q21d $ $ Use of Bevacizumab elected prior to randomization Open: Closed: Target: 27-SEP FEB-2012 (ACRIN JUN-2013) 692 pts (randomized) Chan JK, et al. New Engl J Med, 2016
18 GOG262: Progression-Free Survival (+/- Bevacizumab) Proportion Progression-Free (+) BEV (-) BEV Schedule ( n ) PFS Three-Weekly Dose-Dense Weekly Three-Weekly Dose-Dense Weekly Months on Study Chan JK, et al. New Engl J Med, 2016
19 ICON 8 Design Clamp A et al. ESMO 2017 MRC Clinical Trials Unit at UCL
20 ICON 8 PFS ICON8 Progression Free Survival Arm 1 Arm 2 Arm 3 Standard Weekly Weekly carbopaclitaxel paclitaxel Total Patients N=522 N=523 N=521 Progressions 330 (63%) 335 (64%) 338 (65%) Median PFS 17.9 months 20.6 months 21.1 months Log rank (vs Arm1) p=0.45 p=0.56 HR vs Arm 1 (97.5% CI) 0.92 (0.77, 1.09) 0.94 (0.79, 1.12) Restricted means 24.4 months 24.9 months 25.3 months Accrual began 6 th June 2011 and ICON8 pathway closed to recruitment 28 th November 2014 Final recruitment figure = 1566 UK= 1397, ANZGOG= 70, GICOM= 43, KGOG= 32, ICORG= 24 Primary PFS analysis presented at ESMO Conclusions: although weekly dose-dense chemotherapy can be delivered successfully as first-line EOC treatment without substantial toxicity increase, it does not significantly improve PFS compared to standard 3-weekly CT. Clamp A et al. ESMO 2017 MRC Clinical Trials Unit at UCL
21 Primary Debulking Surgery vs. Neoadjuvant Chemotherapy Dose-Dense Weekly vs. 3-Weekly Paclitaxel Intraperitoneal Chemotherapy Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Maintenance PARP Inhibitors or Bevacizumab in Platinum-Sensitive Relapse
22 Intraperitoneal Chemotherapy 2 heterogeneity (5 d.f.)= 3.1, p=0.68 Hazard ratio is not reported for the GONO study but it is calculated from the available data reported. Hazard ratio is not reported for the Greek study. HR=0.784 (95%CI )
23 IP Chemotherapy GOG 252 Ovarian, Peritoneal, Tubal Cancer Stage II-IV Optimal & Suboptimal (until April 2011) Total Sample Size 1500 R Paclitaxel 80 mg/m 2 IV Days 1, 8, 15 Carboplatin AUC6 IV Day 1 Q3w 6 cycle Bevacizumab 15 mg/kg with chemo plus maintenance 11 cycle Paclitaxel 80 mg/m 2 IV Days 1, 8, 15 Carboplatin AUC6 IP Day 1 Q3w 6 cycle Bevacizumab 15 mg/kg with chemo plus maintenance 11 cycle Paclitaxel 135 mg/m 2 IV Day 1 Cisplatin 75 mg/m 2 IP Day 1 Paclitaxel 60 mg/m 2 IP Day 8 Q3w 6 cycle Bevacizumab 15 mg/kg with chemo plus maintenance 11 cycle
24 IP Chemotherapy GOG 252 Stage II or III Optimally Debulked
25 IP Chemotherapy NCIC OV21 / GCIG Ovarian, Peritoneal, Tubal Cancer Stage IIIC Suboptimal NACT 3cycles IDC Optimal Total Sample Size 830 R Paclitaxel 135 mg/m 2 IV Days 1 Carboplatin AUC6 IV Day 1 Paclitaxel 60 mg/m 2 IV Day 8 Q3w 3 cycle Paclitaxel 135 mg/m 2 IV Day 1 Cisplatin 75 mg/m 2 IP Day 1 Paclitaxel 60 mg/m 2 IP Day 8 Q3w 3 cycle Paclitaxel 80 mg/m 2 IV Day 1 Carboplatin AUC6 IP Day 1 Paclitaxel 60 mg/m 2 IV Day 8 Q3w 3 cycle Pick the Winner
26 IP Chemotherapy NCIC OV21 / GCIG PD Rate at 9 Months Following Randomization (Per-Protocol) Arm 9-month PD rate 95% CI P value Stratified P Value Unstratified % 29.1% to 48.8% PD Rate at 9 Months Following Randomization (ITT) % 16.6% to 34% Stratified: Cochrane-Mantel-Haenszel test Unstratified: Fishers Exact test
27 Intraperitoneal Chemotherapy Outstanding Issues No trial compared with standard chemotherapy with IV carboplatin + IV paclitaxel There are conflicting results on efficacy of IP chemotherapy as first-line therapy. IP is associated with higher toxicity and worsen quality of life compared to IV chemotherapy
28 ipocc Trial (GOTIC 001 / JGOG 3019) Ovarian, Peritoneal, Tubal Cancer Stage II-IV Optimal & Suboptimal Total Sample Size 654 R Paclitaxel 80 mg/m 2 Days 1, 8, 15 IV Carboplatin AUC6 IV Q3w 6-8 cycles Paclitaxel 80 mg/m 2 Days 1, 8, 15 IV Carboplatin AUC6 IP Q3w 6-8 cycles
29 Primary Debulking Surgery vs. Neoadjuvant Chemotherapy Dose-Dense Weekly vs. 3-Weekly Paclitaxel Intraperitoneal Chemotherapy Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Maintenance PARP Inhibitors or Bevacizumab in Platinum-Sensitive Relapse
30 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) March 30 - April 2, 2014 Sheraton Sonoma County Petaluma, California Van Driel WJ et al. N Engl J Med 2018
31 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) March 30 - April 2, 2014 Sheraton Sonoma County Petaluma, California Van Driel WJ et al. N Engl J Med 2018
32 HIPEC: Weaknesses in this trial Due to small number of patients (245) the survival benefit differs by only 15 patients. More unfavourable non-high-grade (mucinous, clear-cell, high-grade endometrioid, carcinosarcoma) tumors in surgery alone group (13 vs. 3). HIPEC resulted in more toxic effects and longer hospitalization Quality of life comparison not reported.
33 HIPEC: ESMO-ESGO Consensus HIPEC is not the standard of care as first-line treatment HIPEC should be limited to well-designed prospective randomized clinical trials.
34 HIPEC: ONGOIG TRIALS ClinicalTrials.gov Identifier: NCT (randomized); Suk-Joon Chang et al.; N=204 March 30 - April 2, 2014 Experimental arm: NAC-IDS-HIPEC Sheraton Sonoma County Under the clinicians' Petaluma, California decision, HIPEC procedures will be performed at the time of IDS. Procedure: HIPEC (paclitaxel 175mg/m2, 90min; open or closed technique) after IDS. IDS is recommended within 4 weeks after the 3rd NAC cycle. HIPEC procedure is allowed only in case of residual disease less than 5mm. No Intervention arm: NAC-IDS Under the clinicians' decision, HIPEC procedures will not be performed at the time of IDS. ClinicalTrials.gov Identifier: NCT (randomized); Pedro Villarejo Campos et al.; n=94 Experimental arm: HIPEC Primary ovarian cancer FIGO stage II, III or IV or recurrent Drug: HIPEC Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Paclitaxel (175 mg/m2) for 60 minutes at degrees Active Comparator arm: No HIPEC Primary ovarian cancer FIGO stage II, III or IV or recurrent Cytoreductive surgery without HIPEC Procedure: No HIPEC
35 Primary Debulking Surgery vs. Neoadjuvant Chemotherapy Dose-Dense Weekly vs. 3-Weekly Paclitaxel Intraperitoneal Chemotherapy Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Maintenance PARP Inhibitors or Bevacizumab in Platinum-Sensitive Relapse
36 Antiangiogenic therapy Bevacizumab in Recurrent Ovarian Cancer: Platinum-Sensitive Relapse 2 positive trials Improved PFS by adding bevacizumab to platinum based chemo and subsequent maintenance therapy OCEANS: PFS CG+/-Bev HR 0.484; 95% CI , p<0.001 GOG 213: TC +/- Bev HR 0.61; 95%CI , p< Aghajanian C et al. J Clin Oncol 2012 Coleman RA et al. SGO 2015
37 Antiangiogenic therapy Bevacizumab in Recurrent Ovarian Cancer: Platinum-Resistant Relapse 1 positive trial Improved PFS by adding bevacizumab to non-platinum based chemo + QoL benefit in symptomatic pts. AURELIA: PFS NonPlat +/- Bev HR 0.48; 95% CI , p< AURELIA: Primary and sensitivity analysis of the primary hypothesis ( 15% improvement in symptomatic pts) Pujade-Lauraine E... Mirza MR et al. J Clin Oncol 2014 Stockler MR... Mirza MR et al. J Clin Oncol 2014
38 ENGOT-OV16 / NOVA Niraparib, as a selective PARP1/2 inhibitor, will provide a clinical benefit to all patients who have platinum-sensitive recurrent ovarian cancer who are in response to platinum, regardless of gbrca mutation status gbrcamut n 203 Platinum-Sensitive Recurrent High Grade Serous Ovarian Cancer Treatment with 4-6 Cycles of Platinum-based Therapy Response to Platinum Treatment n 553 Non-gBRCAmut n 350 2:1 Randomization 2:1 Randomization Niraparib 300 mg once daily Placebo Niraparib 300 mg once daily Placebo Treat until Progression of Disease Treat until Progression of Disease Mirza MR et al. N Engl J Med 2016;375:
39 ENGOT-OV16 / NOVA: PFS Phase 3 randomised trial of maintenance niraparib in platinum-sensitive high-grade serous relapse OC PFS: gbrcamut March 30 - April 2, 2014 Sheraton Sonoma PFS County Petaluma, Median California (95% CI) Treatment (Months) Niraparib 21.0 (N=138) (12.9, NE) 0.27 Placebo 5.5 (N=65) (3.8, 7.2) Hazard Ratio (95% CI) p-value (0.173, 0.410) p< % of Patients without Progression or Death 12 mo 18 mo 62% 50% 16% 16% Treatment Niraparib (N=234) Placebo (N=116) PFS: non-gbrcamut PFS Median (95% CI) (Months) 9.3 Hazard Ratio (95% CI) p-value (7.2, 11.2) (0.338, 0.607) (3.7, 5.5) p< % of Patients without Progression or Death 12 mo 18 mo 41% 30% 14% 12% Progression free Survival (%) Niraparib Placebo Time Since Randomization (months) Mirza MR et al. N Engl J Med 2016;375:
40 Available data from Maintenance Therapy in ovarian cancer Phase 3 NOVA 1 Phas 2 Study 19 2 Phase 3 SOLO2 3 gbrca patients Chemotherapy 6 months 5.5 n= n= n= n=74 Δ15-5 Δ6.9 Δ mo PFS 21 n= n=196 non-gbrca patients Chemotherapy 6 months 3.9 not studied n= n= n=57 n= mo PFS Δ5.4 Δ1.9 Phase 3 GOG213 5 OCEANS 6 BRCA status not determined Chemotherapy 6 months = = = = 8.4 n=242 n=337 n=242 n=337 Δ3.4 Δ4.0 Phase 3 ARIEL n= n=130 Δ11.2 not studied as a cohort PFS = progression free survival; BRCA = breast cancer gene Treatment Placebo 1. Mirza, M.R. et al., New England Journal of Medicine, vol. 375, no. 22, 2016, pp ; 2. Ledermann J. et al., Lancet Oncology, vol. 15, no. 8, 2014, pp ; 3. Pujade-Lauraine, E. et al., Lancet Oncology, vol. 18, no. 9, 2017, pp ; 4. Coleman, R.L. et al., Lancet, vol. 390, no , 2017, pp , 5. Coleman et al., Lancet Oncology, vol. 18, no. 6, 2017, pp ; 6. Aghajanian, C. et al., Journal of Clinical Oncology, vol. 30, no. 17, 2012, pp
41 고맙습니다
Tarceva Trial EORTC 55041
Tarceva Trial EORTC 55041 Primary Chemotherapy Tarceva consolidation 2 years Control Patients closed / 835 Leading Participating EORTC AGO-AUSTRIA, ANZGOG, GINECO, MRC/NCIC, MANGO Randomised trial on Erlotinib
More informationFoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
More informationGOG-172: Survival Outcomes
CHEMOTHERAPY GOG-172: Survival Outcomes Progression-Free Survival Overall Survival Proportion Progression-Free 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 Rx Group IV IP PF Failed Total 50 160 210 63 142
More informationCurrent GCIG Trials in Ovarian Cancer
Lead Grou p Log Current GCIG Trials in Ovarian Cancer Andres Poveda, MD GCIG Chair PARSGO Marrakech April 2018 History of GCIG Collaboration 1992 Collaboration on two studies of paclitaxel in ovarian cancer
More informationCurrent state of upfront treatment for newly diagnosed advanced ovarian cancer
Current state of upfront treatment for newly diagnosed advanced ovarian cancer Ursula Matulonis, M.D. Associate Professor of Medicine, HMS Program Leader, Medical Gyn Oncology Dana-Farber Cancer Institute
More informationACRIN Gynecologic Committee
ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic
More informationTREATMENT FOR RELAPSING PLATINUM SENSITIVE EPITHELIAL OVARIAN CANCER
TREATMENT FOR RELAPSING PLATINUM SENSITIVE EPITHELIAL OVARIAN CANCER Sandro Pignata, MD, PhD Sabrina Chiara Cecere, MD Uro-Gynecological Department, Division of Medical Oncology, IRCCS National Cancer
More informationGOG212: Taxane Maintenance
GOG212: Taxane Maintenance Epithelial Ovarian or Primary Peritoneal Cancer Optimal or Suboptimal Cytoreduction Clinical C with normal CA125, no symptoms, normal CT Primary Carboplatin and Paclitaxel (or
More informationJemal A, Siegel R, Ward E, et al: Cancer statistics, CA: Cancer J Clin 59(4):225-49, 2009
Ovarian cancer 2010-22,500 cases diagnosed per year in the United States and 16,500 deaths per year1. - Most patients are diagnosed in late stages; no screening test exists. - Pathology: 4 different types
More informationClinical Trials. Ovarian Cancer
1.0 0.8 0.6 0.4 0.2 0.0 < 65 years old 65 years old Events Censored Total 128 56 184 73 35 108 0 12 24 36 48 60 72 84 27-10-2012 Ovarian Cancer Stuart M. Lichtman, MD Attending Physician 65+ Clinical Geriatric
More informationbreast and OVARIAN cancer
breast and OVARIAN cancer DR DAVID FENNELLY CONSULTANT MEDICAL ONCOLOGIST ST VINCENT S UNIVERSITY HOSPITAL DUBLIN HOW RELEVANT IS ONCOLOGY IN MEDICINE TODAY? Cancer is the second leading cause of death
More informationThe Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology
The Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology April 26, 2013 Larry J. Copeland M.D. Thank You for Your Friendship! 1982 1996 2013 The Ohio State University
More informationCo-Chairs Helen J MacKay and Diane Provencher On behalf of the OV21/PETROC Investigators CCTG, NCRI (UK), GEICO and SWOG
OV21/PETROC: A Randomized Gynecologic Cancer Intergroup (GCIG) Phase II Study of Intraperitoneal (IP) vs. Intravenous (IV) Chemotherapy Following Neoadjuvant Chemotherapy and Optimal Debulking Surgery
More informationIntraperitoneal chemotherapy: where are we going? A. Gadducci Pisa
Intraperitoneal chemotherapy: where are we going? A. Gadducci Pisa Intraperitoneal Chemotherapy (IP) in advanced ovarian cancer (EOC): Rationale The spread of disease is often limited to the peritoneal
More informationA New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG
A New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG Arizona Oncology (US Oncology Network) Professor, Gynecologic Oncology University of Arizona and Creighton
More informationThe OReO Study. Study design & Protocol Study design Key Inclusion criteria Patient population Recruitment and retention tools
The OReO Study A Phase IIIb, Randomised, Double-blind, Placebo-controlled, multi-centre Study of Olaparib Maintenance Re-treatment in Patients with Epithelial Ovarian Cancer Previously treated with a and
More informationInhibidores de PARP en cáncer de ovario
Inhibidores de PARP en cáncer de ovario Ma Pilar Barretina Ginesta Servicio Oncología Médica Hospital Universitari Dr. J. Trueta Institut Català d Oncologia Coordinación científica: Dr. Fernando Rivera
More informationTRUST Trial on Radical Upfront Surgical Therapy
AGO OP.7 / TRUST TRUST Trial on Radical Upfront Surgical Therapy A close international cooperation ENGOT ov33 Ongoing Trials status update AGO-OVAR OP.7 / TRUST ENGOT-ov33 Trial setting: Sponsor: Pt with
More informationCurrent Medical Oncology Approaches to Gynecologic Cancers. Mihaela Cristea, MD Associate Professor Medical Oncology
Current Medical Oncology Approaches to Gynecologic Cancers Mihaela Cristea, MD Associate Professor Medical Oncology Nothing to disclose DISCLOSURE Ovarian Cancer Objectives: a. To discuss new FDA approved
More informationESMO SUMMIT AFRICA. Latest evidence and current standard of care in advanced ovarian cancer. C.Sessa. Cape Town February 2018
ESMO SUMMIT AFRICA Latest evidence and current standard of care in advanced ovarian cancer C.Sessa IOSI, Bellinzona, CH Cape Town 14-16 February 2018 CONFLICT OF INTEREST DISCLOSURE None Ovarian carcinoma
More informationPractical Guidance and Strategies for PARP Inhibition. Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy
Practical Guidance and Strategies for PARP Inhibition Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy Clinical Data Maintenance therapy : BRCA-mutated or all
More informationOvarian Cancer: New insights into biology and treatment
Ovarian Cancer: New insights into biology and treatment 2018 Master Class Course Ursula A. Matulonis, MD Director, Gynecologic Oncology Brock-Wilson Family Chair Dana-Farber Cancer Institute Professor
More informationPROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC
PROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC Giorgia Mangili RUF ginecologia oncologica medica IRCCS San Raffaele Milano mangili.giorgia@hsr.it STANDARD CHEMOTHERAPY The standard chemotherapy
More informationNew Treatments for Early Ovarian Cancer. Jonathan Ledermann UCL Cancer Institute University College London
New Treatments for Early Ovarian Cancer Jonathan Ledermann UCL Cancer Institute University College London Lucerne Oct 213 Progression-free survival in first-line trials of platinum-based chemotherapy 1998
More informationSide Effects. PFS (months) Study Regimen No. patients. OS (months)
Study Regimen No. patients PFS (months) OS (months) Side Effects Phase II PR ov ca 1 Phase II GOG PR+PS ov ca 1 Bev (15 mg/kg) q3wks Bev (15 mg/kg) q3wks 44 4.4 10.7 HTN, Proteinuria, GI perf (11%) stopped
More informationTable Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies
Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Uterus Study N Eligibility Regimen RR (No. of Responses) Median OS Grade 3/4 Toxicities Nimeiri et al[42] Total:
More informationU T C H. No disclosure
D U GOG T C H Randomized phase 3 trial comparing primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for stage III epithelial ovarian cancer: OVHIPEC-2 Willemien van
More informationVirtual Journal Club. Ovarian Cancer. Reference Slides. Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies
Virtual Journal Club Ovarian Cancer Reference Slides Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies Mansoor R. Mirza, MD Copenhagen University Hospital Rigshospitalet
More informationDrug Niraparib Olaparib
Dear NCCN Value Pathway Committee, We are making this submission to provide information that we believe is relevant for developing NCCN Categories of Preference for the use of PARP inhibitors in recurrent
More information10/24/14. Grand Rounds in Ovarian Cancer: Standards of Care and Novel Treatment Approaches. Disclosure. Learning Objectives
10/24/14 Grand Rounds in Ovarian Cancer: Standards of Care and Novel Treatment Approaches Jessica Gahres, PA-C Memorial Sloan Kettering Cancer Center Don S. Dizon, MD Massachusetts General Hospital Cancer
More informationNCCN Guidelines for Ovarian Cancer V Meeting on 11/15/17
OV-1 External request: Submission from Vermillion/ASPiRA Laboratories to consider: Inclusion of the following recommendation in the workup for suspected ovarian cancer: OVA1 and/or Multivariate Index Assay
More informationResidual Tumor Following Surgery: The Strongest Prognostic Factor or a Myth? Philipp Harter, MD Kliniken Essen Mitte Essen, Germany
Residual Tumor Following Surgery: The Strongest Prognostic Factor or a Myth? Philipp Harter, MD Kliniken Essen Mitte Essen, Germany What Are Our Questions Q1: Prognostic factor residual disease? Q2: Differences
More informationOVARIAN CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
1 OVARIAN CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Source: UpToDate 2017, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze (Gynecologic
More informationOvarian Cancer: Implications for the Pharmacist
Ovarian Cancer: Implications for the Pharmacist Megan May, Pharm.D., BCOP Objectives Describe the etiology and pathophysiology of ovarian cancer Outline the efficacy and safety of treatment options for
More informationsymposium article Optimal primary therapy of ovarian cancer M. A. Bookman* introduction symposium article
Annals of Oncology 27 (Supplement 1): i58 i62, 2016 doi:10.1093/annonc/mdw088 Optimal primary therapy of ovarian cancer M. A. Bookman* Arizona Oncology and US Oncology Research, Tucson, AZ, USA Background:
More informationNordic Society of Gynaecological Oncology
Nordic Society of Gynaecological Oncology - from a Nordic interest group to a global leader in clinical trials Line Bjørge 14. mars 2017 I 1 Profile NSGO is a non-political, non-profit society Nordic platform
More informationBEATcc Trial: ENGOT-Cx10 / GEICO 68-C / JGOG1084. GCIG Meeting
BEATcc Trial: ENGOT-Cx10 / GEICO 68-C / JGOG1084 GCIG Meeting Ana Oaknin, MD PhD Head of Gynecologic Cancer Program. Vall d Hebron Institute of Oncology(VHIO). Vall d Hebron University Hospital. GEICO
More informationTrial record 1 of 1 for:
Find Studies About Studies Submit Studies Resources About Site Trial record 1 of 1 for: YO39523 Previous Study Return to List Next Study A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel,
More informationSOLO-1. Dott.ssa Elisabetta Sanna U.O.C. Ginecologia Oncologica- AOB Cagliari Direttore: Dott. Antonio Macciò
SOLO-1 maintenance therapy in patients with newly diagnosed advanced ovarian cancer following platinum-based chemotherapy Dott.ssa Elisabetta Sanna U.O.C. Ginecologia Oncologica- AOB Cagliari Direttore:
More informationRandomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer
Randomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer Deborah K. Armstrong, M.D. Associate Professor of Oncology, Gynecology and Obstetrics Development of Intraperitoneal
More informationCarcinosarcoma Trial rial in s a in rare malign rare mali ancy
Carcinosarcoma Trials in a rare malignancy BACKGROUND Rare and highly aggressive epithelial malignancies Biphasic tumors with epithelial and mesenchymal components Uterine carcinomas (UCS) uncommon with
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationOvarian Cancer. Disclosure. Ovarian Statistics Educational Objectives. The State of Ovarian Care in the US Why aren t we making more progress?
Esteemed Physician Humanitarian Distinguished Citizen Disclosure Ovarian Cancer The State of Ovarian Care in the US Why aren t we making more progress? Dr. Goff has indicated that she has no relevant financial
More informationMITO Phase III TRIALS. May 2009
MITO Phase III TRIALS Sandro Pignata MD PhD May 2009 Liposomal doxorubicin stealth vs carboplatin/paclitaxel in recurrent ovarian cancer patients with platinumfree interval between 6-12 months MITO 8 ENGOT
More informationRANDOMISED PHASE III STUDY OF ERLOTINIB VERSUS OBSERVATION IN PATIENTS WITH NO EVIDENCE OF DISEASE PROGRESSION AFTER FIRST LINE, PLATINUM-BASED
RANDOMISED PHASE III STUDY OF ERLOTINIB VERSUS OBSERVATION IN PATIENTS WITH NO EVIDENCE OF DISEASE PROGRESSION AFTER FIRST LINE, PLATINUM-BASED CHEMOTHERAPY FOR HIGH- RISK STAGE I AND STAGE II-IV OVARIAN
More informationOriginal Research. Open Access
To cite: Milani A, Kristeleit R, McCormack M, et al. Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy.
More informationLate recurrent epithelial ovarian cancer
Late recurrent epithelial ovarian cancer Dominic Richards University of Cape Town and New Somerset Hospital Gynaecological Oncology Unit September 2016 LATE RECURRENT EPITHELIAL OVARIAN CANCER Background
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationNSGO CLINICAL TRIALS IN OVARIAN CANCER UPDATE
NSGO CLINICAL TRIALS IN OVARIAN CANCER UPATE Niraparib and niraparibbevacizumab combination against bevacizumab alone in Women with Homologous Recombination eficient (HR) platinumsensitive epithelial ovarian,
More informationOVARIAN CANCER Updated July 2015 by: Dr. Jenny Ko (PGY 5 Medical Oncology Resident, University of Calgary)
1 OVARIAN CANCER Updated July 2015 by: Dr. Jenny Ko (PGY 5 Medical Oncology Resident, University of Calgary) Source: UpToDate 2015, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze
More informationTargeted Molecular Therapy Gynaecological Cancer Where are we now?
Targeted Molecular Therapy Gynaecological Cancer Where are we now? 0 T O M D E G R E V E S U B - S P E C I A LT Y F E L L O W G Y N A E C O L O G I C A L O N C O L O G Y U N I V E R S I T Y O F P R E T
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationAngiogenesis in Ovarian Cancer
Angiogenesis in Ovarian Cancer Dr Shibani Nicum Consultant Medical Oncologist and Lead for Gynae- Oncology Oxford University Hospitals Content 1. Epithelial Ovarian Cancer : epidemiology 2. Angiogenesis-normal
More informationBowtell DD, et al. Rethinking ovarian cancer II. Nature Reviews Cancer 15:668-79, A Perspective on Gynecologic Cancers: ASCO 2018
Bowtell DD, et al. Rethinking ovarian cancer II. Nature Reviews Cancer 15:668-79, 2015 A Perspective on Gynecologic Cancers: ASCO 2018 Michael A Bookman MD Director, Gynecologic Oncology Therapeutics The
More informationCómo Incorporar la Terapia Antiangiogénica en el Cáncer de Ovario? XIV Congreso Nacional Salamanca Octubre de 2013 SESION CONTROVERSIA-1 15,45-17H
Cómo Incorporar la Terapia Antiangiogénica en el Cáncer de Ovario? XIV Congreso Nacional Salamanca Octubre de 2013 SESION CONTROVERSIA-1 15,45-17H Andres Poveda Fundación Instituto Valenciano de Oncología
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY
ESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY LUGANO, MAY 4-5, 2018 Clinical development in ovarian cancer C. Sessa, CH CONTENT Rationale for immunotherapy in ovarian cancer Clinical data with single agent immune
More informationNew targets in endometrial and ovarian cancer
New targets in endometrial and ovarian cancer SAMO Interdisciplinary Workshop on Gynecologic Tumors Luzern, January 16-17, 2016 C. Sessa IOSI Bellinzona Outline New targets in ovarian cancer - Cell cycle
More informationSurgery in Recurrent Ovarian Cancer - an emerging area of evidence -
Surgery in Recurrent Ovarian Cancer - an emerging area of evidence - Andreas du Bois Kliniken Essen Mitte (KEM), Germany AdB 2018 A long and winding road to define the role of surgery in relapsed OC called
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationOutcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single
More informationGCIG Rare Tumour Brainstorming Day
GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationThe Role of PARP Inhibitors in Ovarian Cancer: An Emerging Picture
The Role of PARP Inhibitors in Ovarian Cancer: An Emerging Picture This satellite symposium took place on 10 th September 2017 as part of the European Society for Medical Oncology (ESMO) Congress in Madrid,
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationWinship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer
Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Ira R. Horowitz, MD, SM, FACOG, FACS John D. Thompson Professor and Chairman Department of Gynecology
More informationReview Heated Intraperitoneal Chemotherapy in the Management of Ovarian Cancer
Review Heated Intraperitoneal Chemotherapy in the Management of Ovarian Cancer Andrea Jewell 1, Megan McMahon 1 and Dineo Khabele 1 1 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology,
More informationMarcello Deraco M.D. Responsible Peritoneal Malignancies
Perspectives in clinical research for the treatment of peritoneal carcinomatosisin from ovarian cancer Marcello Deraco M.D. Responsible Peritoneal Malignancies Advisable limits of cytoreduction Survey
More informationPARP Inhibitors: Patients Selection. Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016
PARP Inhibitors: Patients Selection Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016 OVARIAN CANCER (OC): MULTIPLES DISEASES Different types with different behaviour
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationRationale for VEGFR-targeted Therapy in RCC
Rationale for VEGFR-targeted Therapy in RCC EIKCS, Budapest, May 2013 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial Management Group Honoraria Astra Zeneca + + + Astellas
More informationFrom Research to Practice: What s New in Gynecologic Cancers?
From Research to Practice: What s New in Gynecologic Cancers? David Warshal, M.D. Head, Division of Gynecologic Oncology MD Anderson Cooper Cancer Institute Associate Professor of Obstetrics and Gynecology
More informationOverall survival results of ICON6: a trial of chemotherapy and cediranib in relapsed ovarian cancer
Overall survival results of ICON6: a trial of chemotherapy and in relapsed ovarian cancer Ledermann JA, Embleton AC, Perren T, Jayson GC, Rustin GJS, Kaye SB, Hirte HW, Oza AM, Vaughan MM, Friedlander
More informationCERVICAL/VULVAR CANCER CLINICAL TRIALS
CERVICAL/VULVAR CANCER CLINICAL TRIALS ALL-COMERS Primary Treatment Locally Advanced Recurrent Cervical GTFB (07-0935) TISSUE BANK ALL GYN TISSUE ETCTN (Phase II) (17-0458) LAO-MD017/#10010 Phase II Study
More informationSurvival impact of cytoreductive surgery ın advanced stage EOC
Survival impact of cytoreductive surgery ın advanced stage EOC Ayhan Ali, MD Baskent University School of Medicine Department of Obstetrics and Gynecology, Division of Gynecologic Oncology 1 OVARIAN CANCER
More informationTrabectedina + PLD nel trattamento del carcinoma ovarico. Nicoletta Colombo Universita Milano Bicocca Istituto Europeo Oncologia Milano
Trabectedina + PLD nel trattamento del carcinoma ovarico Nicoletta Colombo Universita Milano Bicocca Istituto Europeo Oncologia Milano The old definition of Recurrent Ovarian Cancer P R I M A R Y T H E
More informationTreatment of Recurrent Ovarian Cancer
Treatment of Recurrent Ovarian Cancer Mihaela Cristea, MD Associate Professor Medical Oncology, City of Hope November 11, 2016 No disclosures Financial Disclosure Epithelial Ovarian Cancer Subtypes and
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationSafety Findings From FORWARD II: A Phase Ib Study Evaluating the Folate Receptor Alpha (FR
Safety Findings From FORWARD II: A Phase Ib Study Evaluating the Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC) Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab,
More informationEligibility Form. 1. Patient Profile. (This form must be completed before the first dose is dispensed.) Request prior approval for enrolment
Bevacizumab in combination with Paclitaxel and Carboplatin - Frontline Treatment (Previously Untreated) Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (This form must be completed before the first
More informationESMO SUMMIT MIDDLE EAST 2018
ESMO SUMMIT MIDDLE EAST 2018 Practice changing studies in Gynecological Cancer in 2017 Dr Susana Banerjee MBBS MA PhD FRCP Consultant Medical Oncologist and Research Lead Gynaecology Unit The Royal Marsden
More informationOriginal Research. Background
Original Research 849 in Carboplatin and Dose-Dense Paclitaxel Chemotherapy for Ovarian Malignancies: A Survey of NCCN Member Institutions Marina Stasenko, MD a ; R. Kevin Reynolds, MD a ; Carolyn Johnston,
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationSurveillance report Published: 17 March 2016 nice.org.uk
Surveillance report 2016 Ovarian Cancer (2011) NICE guideline CG122 Surveillance report Published: 17 March 2016 nice.org.uk NICE 2016. All rights reserved. Contents Surveillance decision... 3 Reason for
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationRadiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK
Lead Group Log Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK Cervical Cancer treatment Treatment planning should be made on a multidisciplinary
More informationASCO- GYN Abstracts 8/3/2011. Susana Campos, MD, MPH. Boston Mass. Prevention. Maintenance. Recurrent Disease.
ASCO- GYN- 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Boston Mass Prevention Maintenance Recurrent Disease Abstracts 5001: Effect of screening on ovarian cancer mortality in the Prostate,
More informationGynecologic Oncology Unit IRCCS Istituto Tumori Milano G. Maltese. Milan - Italy
Gynecologic Oncology Unit IRCCS Istituto Tumori Milano G. Maltese Milan - Italy Mutations typically associated with ovarian carcinoma subtypes High-grade serous ovarian cancer TP53: encodes a protein that
More informationExpert Call Innovation in Ovarian Cancer Hosted by John Sonnier, William Blair. December 13, 2016
Expert Call Innovation in Ovarian Cancer Hosted by John Sonnier, William Blair December 13, 2016 1 Forward-Looking Statements This presentation includes forward-looking statements based on management's
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationSGOG (Xi Cheng) Carcinoid tumor GICOM (Eva Gomez) EORTC (N Reed)
Leiden, Dec 2012 Subject 1st coordonator Sub coordonator Ov & Ut Carcinosarcoma GINECO (D Berton Rigaud) Low Malignant Potential Tumors AGO (P Harter) Low grade serous carcinoma GOG (D Gershenson) MRC/NCRI
More informationGCIG Rare Tumor Working Group Report. David M. Gershenson Isabelle Ray-Coquard
GCIG Rare Tumor Working Group Report David M. Gershenson Isabelle Ray-Coquard Thursday 31 st May 2012 Ted Trimble IRCI - Aims To facilitate the development of international clinical trials of treatments
More informationSummary... 2 GYNAECOLOGICAL CANCER Niraparib in second-line treatment for platinum sensitive recurrant ovarian cancer... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 GYNAECOLOGICAL CANCER... 3 Niraparib in second-line treatment for platinum sensitive recurrant ovarian cancer...
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationDr Sarah Mc Kenna, Consultant Medical Oncologist and Dr Joanne Millar, Consultant Medical Oncologist
Title: Systemic Anti-Cancer Therapy (SACT) Guidelines for Ovarian Cancer Author(s) Ownership: Approval by: Operational Date: Dr Sarah Mc Kenna, Consultant Medical Oncologist and Dr Joanne Millar, Consultant
More informationHow to fight a silent killer: Lessons learned from Ovarian Cancer. Stephen A. Cannistra, M.D.
How to fight a silent killer: Lessons learned from Ovarian Cancer Stephen A. Cannistra, M.D. How to fight a silent killer: Lessons learned from Ovarian Cancer Ovarian cancer is not common but is highly
More informationUpdate on PARP inhibitors: opportunities and challenges in cancer therapy
Update on PARP inhibitors: opportunities and challenges in cancer therapy Vanda Salutari Unità di Ginecologia Oncologica Fondazione Policlinico Universitario A. Gemelli vanda.salutari@policlinicogemelli.it
More information